U19AI162130
Cooperative Agreement
Overview
Grant Description
Evaluating Modes of Influenza Transmission (EMIT-2) Using Innovative Technologies and Designs in Controlled Environments - Project Summary/Abstract – Overall Component
We propose multidisciplinary studies to comprehensively evaluate the roles of contact, fomite, sprayborne, and aerosol transmission and how they interact with ventilation to facilitate human-to-human influenza transmission. We will utilize a suite of innovative technologies for improved sampling, fractionation, culture, and characterization of influenza virus aerosols. These studies leverage our highly diverse team of experts in bioengineering, aerosol science, human challenge and clinical trials, influenza virology and immunology, infectious diseases epidemiology, aerobiology, and computational fluid dynamics.
The proposal is organized around two research projects and three cores. In Research Project 1, "Evaluating Modes of Influenza Transmission Using a Randomized Controlled Trial (EMIT-2-RCT)," we will study the impact of two interventions: a) ventilation and air sanitation, and b) hand hygiene and face shields on the transmission of circulating seasonal influenza from naturally infected cases to serologically susceptible volunteers. We will use the RCT to test hypotheses that aerosol transmission is the dominant mode, is associated with a greater frequency of fever and systemic symptoms in secondary cases, and that in the absence of hemagglutination inhibiting antibodies, antibodies against other targets will strongly correlate with protection from infection and disease.
In Research Project 2, "Developing and Applying Analytical Models of Influenza Transmission," we will use computational fluid dynamics and novel aerosol measurements to: a) design interventions and sampling strategies for the RCT enabling us to distinguish short- and long-range aerosol transmission from sprayborne transmission, b) define the Wells-Riley aerosol quantum of infection in terms of measurable quantities and assess risk at the recipient breathing zone level in both well-mixed and non-well-mixed indoor air conditions, and c) extend our models to household and animal studies and create practical analytical tools for public health scientists to collect data and assess risk in the field.
The research projects will be enabled by an Advanced Bioaerosol Technology Core (ABTC) that will develop new viral aerosol sampling and culture systems and methods for both ambient and exhaled breath sampling. These systems will validate the RCT design and provide critical inputs to the analytical models. A Clinical and Biostatistics Core (CBC) will provide the clinical infrastructure to perform the complex quarantine studies. The Administrative Core will manage these tightly integrated components to mold transdisciplinary insights into the dynamics and drivers of influenza transmission between humans.
We propose multidisciplinary studies to comprehensively evaluate the roles of contact, fomite, sprayborne, and aerosol transmission and how they interact with ventilation to facilitate human-to-human influenza transmission. We will utilize a suite of innovative technologies for improved sampling, fractionation, culture, and characterization of influenza virus aerosols. These studies leverage our highly diverse team of experts in bioengineering, aerosol science, human challenge and clinical trials, influenza virology and immunology, infectious diseases epidemiology, aerobiology, and computational fluid dynamics.
The proposal is organized around two research projects and three cores. In Research Project 1, "Evaluating Modes of Influenza Transmission Using a Randomized Controlled Trial (EMIT-2-RCT)," we will study the impact of two interventions: a) ventilation and air sanitation, and b) hand hygiene and face shields on the transmission of circulating seasonal influenza from naturally infected cases to serologically susceptible volunteers. We will use the RCT to test hypotheses that aerosol transmission is the dominant mode, is associated with a greater frequency of fever and systemic symptoms in secondary cases, and that in the absence of hemagglutination inhibiting antibodies, antibodies against other targets will strongly correlate with protection from infection and disease.
In Research Project 2, "Developing and Applying Analytical Models of Influenza Transmission," we will use computational fluid dynamics and novel aerosol measurements to: a) design interventions and sampling strategies for the RCT enabling us to distinguish short- and long-range aerosol transmission from sprayborne transmission, b) define the Wells-Riley aerosol quantum of infection in terms of measurable quantities and assess risk at the recipient breathing zone level in both well-mixed and non-well-mixed indoor air conditions, and c) extend our models to household and animal studies and create practical analytical tools for public health scientists to collect data and assess risk in the field.
The research projects will be enabled by an Advanced Bioaerosol Technology Core (ABTC) that will develop new viral aerosol sampling and culture systems and methods for both ambient and exhaled breath sampling. These systems will validate the RCT design and provide critical inputs to the analytical models. A Clinical and Biostatistics Core (CBC) will provide the clinical infrastructure to perform the complex quarantine studies. The Administrative Core will manage these tightly integrated components to mold transdisciplinary insights into the dynamics and drivers of influenza transmission between humans.
Funding Goals
NOT APPLICABLE
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
College Park,
Maryland
20742
United States
Geographic Scope
Single Zip Code
Related Opportunity
Analysis Notes
Amendment Since initial award the total obligations have increased 304% from $3,024,086 to $12,220,509.
College Park University Of Maryland was awarded
EMIT-2: Evaluating Influenza Transmission with Innovative Tech
Cooperative Agreement U19AI162130
worth $12,220,509
from the National Institute of Allergy and Infectious Diseases in September 2021 with work to be completed primarily in College Park Maryland United States.
The grant
has a duration of 4 years 8 months and
was awarded through assistance program 93.855 Allergy and Infectious Diseases Research.
The Cooperative Agreement was awarded through grant opportunity Multidisciplinary Studies to Improve Understanding of Influenza Transmission (U19 Clinical Trial Optional).
Status
(Ongoing)
Last Modified 6/20/24
Period of Performance
9/1/21
Start Date
5/31/26
End Date
Funding Split
$12.2M
Federal Obligation
$0.0
Non-Federal Obligation
$12.2M
Total Obligated
Activity Timeline
Subgrant Awards
Disclosed subgrants for U19AI162130
Transaction History
Modifications to U19AI162130
Additional Detail
Award ID FAIN
U19AI162130
SAI Number
U19AI162130-239998225
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Public/State Controlled Institution Of Higher Education
Awarding Office
75NM00 NIH NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
Funding Office
75NM00 NIH NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
Awardee UEI
NPU8ULVAAS23
Awardee CAGE
0UB92
Performance District
MD-04
Senators
Benjamin Cardin
Chris Van Hollen
Chris Van Hollen
Budget Funding
Federal Account | Budget Subfunction | Object Class | Total | Percentage |
---|---|---|---|---|
National Institute of Allergy and Infectious Diseases, National Institutes of Health, Health and Human Services (075-0885) | Health research and training | Grants, subsidies, and contributions (41.0) | $6,124,300 | 100% |
Modified: 6/20/24